Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

Florian Märkl,Christoph Schultheiß,Murtaza Ali,Shih-Shih Chen,Marina Zintchenko,Lukas Egli,Juliane Mietz,Obinna Chijioke,Lisa Paschold,Sebastijan Spajic,Anne Holtermann,Janina Dörr,Sophia Stock,Andreas Zingg,Heinz Läubli,Ignazio Piseddu,David Anz,Marcus Dühren-von Minden,Tianjiao Zhang,Thomas Nerreter,Michael Hudecek,Susana Minguet,Nicholas Chiorazzi,Sebastian Kobold,Mascha Binder

DOI: https://doi.org/10.1038/s41467-024-45378-w

IF: 16.6

2024-02-02

Nature Communications

Abstract:Abstract The concept of precision cell therapy targeting tumor-specific mutations is appealing but requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of mature lymphoid malignancies are exceptional in that they harbor tumor-specific-stereotyped sequences in the form of point mutations that drive self-engagement of the BCR and autologous signaling. Here, we use a BCR light chain neoepitope defined by a characteristic point mutation (IGLV3-21 R110 ) for selective targeting of a poor-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. We develop murine and humanized CAR constructs expressed in T cells from healthy donors and CLL patients that eradicate IGLV3-21 R110 expressing cell lines and primary CLL cells, but neither cells expressing the non-pathogenic IGLV3-21 G110 light chain nor polyclonal healthy B cells. In vivo experiments confirm epitope-selective cytolysis in xenograft models in female mice using engrafted IGLV3-21 R110 expressing cell lines or primary CLL cells. We further demonstrate in two humanized mouse models lack of cytotoxicity towards human B cells. These data provide the basis for advanced approaches of resistance-preventive and biomarker-guided cellular targeting of functionally relevant lymphoma driver mutations sparing normal B cells.

multidisciplinary sciences